RxDoctor Payments Data

Kristine Smith

Family · Michigan City, INNPI 1053988246

Payments from drug & device makers

$590in general payments, 2019–2025

Across 27 payments — averaging $21.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$201
  • Abbott$54
  • Novartis$53
  • Merck$34
  • Novo Nordisk$34
  • Scpharmaceuticals Inc.$22
  • plus $192 from 11 others

What the payments were for

  • Food & beverage$590100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$590 in reported general payments places this provider in the 55th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$46,638
Medicare patients
230
Services billed
622

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide16$20,454
TrulicityDulaglutide19$19,769
EliquisApixaban26$15,221
JardianceEmpagliflozin16$13,607
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$10,578
Breo ElliptaFluticasone/Vilanterol21$9,049
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$6,998
XareltoRivaroxaban12$6,734
Spiriva RespimatTiotropium Bromide11$5,699
FarxigaDapagliflozin Propanediol13$3,717
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$3,487
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$2,387
Albuterol Sulfate HfaAlbuterol Sulfate63$1,309
Gabapentin94$866
Mirtazapine45$780

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$34$20,45416 claims
Lilly USA, LLCTrulicity$22$19,76919 claims
GSKTrelegy Ellipta, Breo Ellipta$16$19,62737 claims
Boehringer IngelheimJardiance, Spiriva Respimat$18$19,30627 claims
PfizerEliquis$16$15,22126 claims
AstraZenecaBreztri Aerosphere, Farxiga$201$10,71624 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,392 family providers in Indiana.

Other family in Michigan City

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →